The Real-World Lifetime Economic Burden of Urothelial Carcinoma by Stage at Diagnosis.

ABSTRACT:

Background

Urothelial carcinoma (UC) is generally diagnosed early and may incur significant lifetime costs. This study estimated, from the payer's perspective, the lifetime costs among patients diagnosed with UC according to stage at diagnosis.

Methods

This retrospective analysis of the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database identified patients ≥66 years with newly diagnosed UC from 2004-2013. Patients were followed from UC diagnosis to death or last follow-up to estimate lifetime costs. Costs were allocated to 3 phases: diagnosis (≤3 months after diagnosis), terminal (≤3 months before death), and continuation (months between diagnosis and terminal phases). Survival-adjusted lifetime costs (total and major UC-related) were estimated for p

SUBMITTER: Aly A 

PROVIDER: S-EPMC7433100 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature